Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NewGenIvf Group Limited Warrants (NIVFW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: NIVFW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -6.25% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.13 | 52 Weeks Range 0.01 - 0.06 | Updated Date 06/3/2025 |
52 Weeks Range 0.01 - 0.06 | Updated Date 06/3/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.66% | Operating Margin (TTM) -85.51% |
Management Effectiveness
Return on Assets (TTM) -17.99% | Return on Equity (TTM) -53.76% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 112699 |
Shares Outstanding - | Shares Floating 112699 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
NewGenIvf Group Limited Warrants
Company Overview
History and Background
NewGenIvf Group Limited is a company focused on assisted reproductive technology (ART). Specific founding year and detailed milestones for the *warrants* themselves, separate from the company, are not readily available without specifying the particular warrant series.
Core Business Areas
- Assisted Reproductive Technology (ART) Services: Provides a range of fertility treatments and services, including in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and preimplantation genetic testing (PGT).
Leadership and Structure
Information on the warrants' leadership is not applicable. The leadership refers to the parent company's management team.
Top Products and Market Share
Key Offerings
- IVF Services: Offers comprehensive IVF services. Market share data is not publicly available for warrant products.
- ICSI Services: Provides ICSI procedures. Market share data is not publicly available for warrant products.
Market Dynamics
Industry Overview
The ART industry is growing due to increasing infertility rates and technological advancements.
Positioning
NewGenIvf Group aims to provide advanced ART services.
Total Addressable Market (TAM)
The global fertility services market is estimated at billions of dollars. NewGenIvf Group's position within this TAM is dependent on their service offerings and geographic footprint.
Upturn SWOT Analysis
Strengths
- Specialized focus on assisted reproductive technology
- Experienced medical professionals
- Advanced technology and equipment
Weaknesses
- Limited geographic presence
- High operating costs
- Dependence on specialized expertise
Opportunities
- Expanding services to new geographic regions
- Developing partnerships with other healthcare providers
- Introducing innovative ART technologies
Threats
- Intense competition from other fertility clinics
- Changes in regulations and reimbursement policies
- Economic downturn impacting demand for ART services
Competitors and Market Share
Key Competitors
Competitive Landscape
The warrant's performance is derived from the parent company, NewGenIvf Group. The advantage of the warrants depend on their strike price and other specific details.
Growth Trajectory and Initiatives
Historical Growth: Warrant growth depends on the underlying stock's historical performance.
Future Projections: Warrant performance will be determined by the stock price trajectory and market conditions.
Recent Initiatives: Recent strategic initiatives would be performed by the parent company not the warrants themselves.
Summary
NewGenIvf Group Limited warrants provide a leveraged investment into the underlying stock. Performance hinges on the company's operational success and market conditions. The warrants are inherently more risky than holding the underlying stock, but offer the potential for higher returns if the stock price appreciates significantly. Investors need to closely monitor NewGenIvf Group's financials and competitive position.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Market research reports
- Financial news articles
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Warrant performance is linked to the underlying stock. Investors should conduct their own due diligence before investing.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NewGenIvf Group Limited Warrants
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-04-04 | Co-Founder, Chairman & CEO Mr. Wing Fung Siu | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 76 | Website https://newgenivf.com |
Full time employees 76 | Website https://newgenivf.com | ||
NewGenIvf Group Limited, an investment holding company, provides an assisted reproductive service that helps couples and individuals for fertility treatments in Thailand, Cambodia, Hong Kong, and Kyrgyzstan. The company's fertility treatment solutions include in vitro fertilization (IVF), ICSI, embryo culture, hormonal blood tests, infectious diseases tests, chromosome screening, hysteroscopy, sperm analysis, sorting, washing, and freezing, and egg freezing. It also provides IVF treatment; surrogacy and ancillary caring services, including regular body check, as well as vitamins, supplements, and medicines to surrogate mothers; and value-added services comprising nutrition guidance, psychological counselling, acupuncture, and translation interpreters to supplement the IVF treatment. The company offers its services through its clinics. NewGenIvf Group Limited was founded in 2010 and is based in Bangkok, Thailand.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.